highly significantp < 0.001
This strong reduction effect is supported by a highly significant p-value (p < 0.001) and a narrow CI (0.135–0.603), which suggests robust evidence that P2Y12 antagonist use is protective against SCD ( Fig 2 ).
This strong reduction effect is supported by a highly significant p-value (p < 0.001) and a narrow CI (0.135–0.603), which suggests robust evidence that P2Y12 antagonist use is protective against SCD ( Fig 2 ).
did not demonstrate significant MACCE benefits, their data showed a trend toward better survival with DAPT.